Kyburz D, Aichele P, Speiser D E, Hengartner H, Zinkernagel R M, Pircher H
Institute of Experimental Immunology, University of Zürich, Switzerland.
Eur J Immunol. 1993 Aug;23(8):1956-62. doi: 10.1002/eji.1830230834.
The fate of in vivo activated CD8+ cytotoxic T cells was studied in transgenic mice expressing a T cell receptor (TCR) specific for the lymphocytic choriomeningitis virus (LCMV) glycoprotein peptide 33-41 presented by major histocompatibility complex (MHC) class I molecules. LCMV infection of TCR transgenic mice induced LCMV-specific effector and memory T cells whereas injection of soluble LCMV glycoprotein peptide 33-41 resulted in tolerance by peripheral deletion and anergy of LCMV-specific T cells after an initial expansion phase. Similarly, LCMV peptide 33-41-specific tolerance could be achieved in normal C57BL/6 mice and was not abrogated by an LCMV infection. These results obtained with a classically MHC-restricted peptide antigen parallel previous findings with retroviral or bacterial superantigens and indicate a possibility to modulate specifically mature peripheral cytotoxic T lymphocytes in vivo.
在表达针对由主要组织相容性复合体(MHC)I类分子呈递的淋巴细胞性脉络丛脑膜炎病毒(LCMV)糖蛋白肽33 - 41具有特异性的T细胞受体(TCR)的转基因小鼠中,研究了体内活化的CD8 + 细胞毒性T细胞的命运。TCR转基因小鼠感染LCMV可诱导出LCMV特异性效应T细胞和记忆T细胞,而注射可溶性LCMV糖蛋白肽33 - 41在初始扩增阶段后会导致LCMV特异性T细胞通过外周清除和无反应性而产生耐受。同样,在正常C57BL / 6小鼠中也可实现LCMV肽33 - 41特异性耐受,且不受LCMV感染的影响。这些使用经典MHC限制性肽抗原获得的结果与先前关于逆转录病毒或细菌超抗原的研究结果相似,并表明在体内特异性调节成熟外周细胞毒性T淋巴细胞的可能性。